Tower Research Capital (TRC)’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-800	Closed	-$3K	–	4514
2016 Q4	$3K	Buy	800 +113	+16%	+$466	﹤0.01%	3358
2016 Q3	$3K	Buy	+687	New	+$3.26K	﹤0.01%	2976
2016 Q2	–	Sell	-795	Closed	-$3K	–	5396
2016 Q1	$3K	Sell	795 -1,034	-57%	-$3.37K	﹤0.01%	3249
2015 Q4	$6K	Buy	1,829 +1,542	+537%	+$6.09K	﹤0.01%	2887
2015 Q3	$1K	Sell	287 -963	-77%	-$4.39K	﹤0.01%	3806
2015 Q2	$6K	Buy	1,250 +1,095	+706%	+$7.59K	﹤0.01%	3190
2015 Q1	$1K	Buy	+155	New	+$1.47K	﹤0.01%	4257

Other funds holding NVET

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

LLC

Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s NVET Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q1 2017, closing a stake of 800 shares — an estimated $3K sold.

Tower Research Capital (TRC) first reported a position in NVET in Q1 2015 and held it in 7 quarters. The position peaked at $6K in Q4 2015. 13 funds tracked by Wall St. Rank hold NVET as of Q1 2017.

Tower Research Capital (TRC) reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q1 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 800 Nexvet Biopharma plc Ordinary Shares shares in Q1 2017, an estimated $3K.
Tower Research Capital (TRC) first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 7 quarters.
Tower Research Capital (TRC)'s Nexvet Biopharma plc Ordinary Shares position peaked at $6K in Q4 2015.
13 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.